Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination of an alpha-blocker and a nonsteroidal anti-inflammatory drug (NSAID). Alpha-blockers are a class of medications that inhibit the stimulation of alpha-adrenergic receptors, leading to relaxation of blood vessels and smooth muscle, commonly used for hypertension and benign prostatic hyperplasia. NSAIDs are a class of drugs that provide analgesic, antipyretic, and anti-inflammatory effects by inhibiting cyclooxygenase (COX) enzymes involved in prostaglandin synthesis. This combination is not available as a fixed-dose pharmaceutical product but may be encountered when both classes are prescribed together for comorbid conditions such as hypertension/prostate symptoms with pain or inflammation. Coadministration can lead to clinically significant drug interactions; notably, NSAIDs may reduce the antihypertensive efficacy of alpha-blockers and increase the risk for renal impairment or cardiovascular events[1][2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alpha-blocker + NSAID.